- Home
- CODX vs COEP Comparison
CODX vs COEP Comparison
Compare CODX & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CODX
- COEP
- Stock Information
- Founded
- CODX 2013
- COEP 2017
- Country
- CODX United States
- COEP United States
- Employees
- CODX N/A
- COEP N/A
- Industry
- CODX Medical/Dental Instruments
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CODX Health Care
- COEP Health Care
- Exchange
- CODX Nasdaq
- COEP Nasdaq
- Market Cap
- CODX 23.3M
- COEP 22.3M
- IPO Year
- CODX 2017
- COEP N/A
- Fundamental
- Price
- CODX $0.83
- COEP $10.80
- Analyst Decision
- CODX Hold
- COEP
- Analyst Count
- CODX 1
- COEP 0
- Target Price
- CODX $1.50
- COEP N/A
- AVG Volume (30 Days)
- CODX 305.8K
- COEP 1.0M
- Earning Date
- CODX 03-13-2025
- COEP 11-13-2024
- Dividend Yield
- CODX N/A
- COEP N/A
- EPS Growth
- CODX N/A
- COEP N/A
- EPS
- CODX N/A
- COEP N/A
- Revenue
- CODX $7,321,012.00
- COEP N/A
- Revenue This Year
- CODX N/A
- COEP N/A
- Revenue Next Year
- CODX N/A
- COEP N/A
- P/E Ratio
- CODX N/A
- COEP N/A
- Revenue Growth
- CODX 57.16
- COEP N/A
- 52 Week Low
- CODX $0.67
- COEP $2.31
- 52 Week High
- CODX $2.23
- COEP $13.58
- Technical
- Relative Strength Index (RSI)
- CODX 51.48
- COEP 80.94
- Support Level
- CODX $0.76
- COEP $6.22
- Resistance Level
- CODX $0.88
- COEP $10.00
- Average True Range (ATR)
- CODX 0.10
- COEP 1.81
- MACD
- CODX 0.01
- COEP 0.41
- Stochastic Oscillator
- CODX 37.17
- COEP 100.00
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.